166 related articles for article (PubMed ID: 32708981)
1. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.
Amato CM; Hintzsche JD; Wells K; Applegate A; Gorden NT; Vorwald VM; Tobin RP; Nassar K; Shellman YG; Kim J; Medina TM; Rioth M; Lewis KD; McCarter MD; Gonzalez R; Tan AC; Robinson WA
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708981
[TBL] [Abstract][Full Text] [Related]
2. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
3. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
4. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
5. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
6. Mixed Response to Immunotherapy in Patients with Metastatic Melanoma.
Rauwerdink DJW; Molina G; Frederick DT; Sharova T; van der Hage J; Cohen S; Boland GM
Ann Surg Oncol; 2020 Sep; 27(9):3488-3497. PubMed ID: 32472413
[TBL] [Abstract][Full Text] [Related]
7. A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy.
Bigelow E; Saria S; Piening B; Curti B; Dowdell A; Weerasinghe R; Bifulco C; Urba W; Finkelstein N; Fertig EJ; Baras A; Zaidi N; Jaffee E; Yarchoan M
Cancer Inform; 2022; 21():11769351221136081. PubMed ID: 36439024
[TBL] [Abstract][Full Text] [Related]
8. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.
Lee H; Quek C; Silva I; Tasker A; Batten M; Rizos H; Lim SY; Nur Gide T; Shang P; Attrill GH; Madore J; Edwards J; Carlino MS; Guminski A; Saw RPM; Thompson JF; Ferguson PM; Palendira U; Menzies AM; Long GV; Scolyer RA; Wilmott JS
Oncoimmunology; 2019; 8(2):e1537581. PubMed ID: 30713793
[No Abstract] [Full Text] [Related]
9. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
12.
Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
Front Immunol; 2021; 12():672521. PubMed ID: 34177913
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
14. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients.
Ohuchi K; Kambayashi Y; Hidaka T; Fujimura T
Front Oncol; 2021; 11():798385. PubMed ID: 34912726
[TBL] [Abstract][Full Text] [Related]
16. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
17. Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma.
Nie RC; Yuan SQ; Wang Y; Chen YB; Cai YY; Chen S; Li SM; Zhou J; Chen GM; Luo TQ; Zhou ZW; Li YF
Aging (Albany NY); 2019 Dec; 11(23):11576-11590. PubMed ID: 31796647
[TBL] [Abstract][Full Text] [Related]
18. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Oncotarget; 2018 May; 9(38):25265-25276. PubMed ID: 29861869
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
20.
Liu N; Chen L; Yan M; Tao Q; Wu J; Chen J; Chen X; Zhang W; Peng C
Research (Wash D C); 2023; 6():0127. PubMed ID: 37223471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
